Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
05/2003
05/22/2003US20030096827 Heterocyclic amine derivatives; for treating an inflammatory or immune disease, a cardiovascular disease, or a neurodegenerative condition
05/22/2003US20030096819 Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents
05/22/2003US20030096817 Inhibiting mammalian protein kinases (p38) with (2,6-difluoro-phenyl)-(5-iodo-pyridin-2-yl)amine for treatment of cardiovascular disorders
05/22/2003US20030096816 Such as 2-methylsulfanyl-5-(2-phenylamino-pyrimidin-4-yl)-4-p-tolyl-thiophene-3 -carbonitrile; antiproliferative agents; stents
05/22/2003US20030096812 Such as 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(4-amino-3-methyl-1 -piperidinyl)-4-oxo-quinoline-3-carboxylic acid for treatment of systemic or topical infections
05/22/2003US20030096796 N-cyanomethyl amides which are cysteine protease inhibitors; use treating diseases associated with activity of cathepsins B, K, L or S such as autoimmune disorders, allergic disorder, allogeneic immune response, cardiovascular disorders
05/22/2003US20030096788 Adenosine derivatives
05/22/2003US20030096783 21132, a human G-protein coupled receptor family member and uses therefor
05/22/2003US20030096771 8-50 nucleobases targeted to a nucleic acid molecule encoding hormone-sensitive lipase to hybridize with and inhibit expression
05/22/2003US20030096758 Anticarcinogenic agents
05/22/2003US20030096756 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/22/2003US20030096746 Compounds and methods for inhibiting cancer metastasis
05/22/2003US20030096739 Nuclear receptor-mediated introduction of a PNA into cell nuclei
05/22/2003US20030096737 Caspase inhibitors and uses thereof
05/22/2003US20030096350 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/22/2003US20030096299 Natural ligand of G protein coupled receptor ChemR23 and uses thereof
05/22/2003US20030096297 Method for identifying inhibitors of G protein coupled receptor signaling
05/22/2003US20030096050 Catechins; gallic acid or a salt thereof; anti-obesity agent with good taste
05/22/2003US20030096030 Extracting materials from the shell of Xanthoceras sorbifolia Bunge and applying the extracted materials to making drugs and functional foods
05/22/2003US20030095983 Treating obesity, insulin resistance, and type II diabetes
05/22/2003US20030095954 Growth factor gene fused with secretory signal sequence is introduced into fibroblasts ex-vivo using adenovirus vector; infecting cultured non-hematocytes with the vector; administering the cells
05/22/2003CA2756866A1 A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
05/22/2003CA2468497A1 Heterocyclic derivatives of glycinamide and their medical use
05/22/2003CA2467347A1 Histamine receptor h3 polynucleotides
05/22/2003CA2467267A1 Phenyl substituted triazoles and their use as selective inhibors of akl5 kinase
05/22/2003CA2467061A1 Sustained release film preparation for local administration comprising prostaglandin derivative as active ingredient
05/22/2003CA2466632A1 Injectable depot compositions and uses thereof
05/22/2003CA2466519A1 Method for treating autoimmune diseases
05/22/2003CA2466465A1 Nk1 antagonists
05/22/2003CA2466440A1 Cannabinoid receptor ligands
05/22/2003CA2466415A1 Pgc-1.beta., a novel pgc-1 homologue and uses therefor
05/22/2003CA2466264A1 Three-dimensional structure of prostaglandin d synthase and utilization thereof
05/22/2003CA2466115A1 Cyanoalkylamino derivatives as protease inhibitors
05/22/2003CA2466055A1 Substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
05/22/2003CA2465893A1 Polycyclic guanine derivative phosphodiesterase v inhibitors
05/22/2003CA2465868A1 A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
05/22/2003CA2465861A1 Carboxylic acid derivative compounds and drugs containing the same as the active ingredient
05/22/2003CA2464863A1 N-adamantylmethyl derivates and intermediates as pharmaceutical compositions and processes for their preparation
05/22/2003CA2464419A1 Benzimidazoles useful as protein kinase inhibitors
05/22/2003CA2464347A1 Piperidine derivatives and their use as modulators of chemokine receptor activity (especially ccr5)
05/22/2003CA2461481A1 Ptp1b inhibitors and ligands
05/22/2003CA2460959A1 Enzymes
05/21/2003EP1312601A1 Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient
05/21/2003EP1312374A1 Sugar absorption inhibitors and process for producing the same
05/21/2003EP1312367A1 Heterocyclo-alkylsulfonyl pyrazolesa and their use as COX-2 inhibitors
05/21/2003EP1312363A1 Methods of treatment and kits comprising a growth hormone secretagogue
05/21/2003EP1311677A2 Regulation of human p2y1-like g protein-coupled receptor
05/21/2003EP1311543A1 T cell receptor v beta-d beta-j beta sequence and methods for its detection
05/21/2003EP1311534A1 Thioether-sulphamate steroids as steroid sulphatase inhibitors and anti-cancer compounds
05/21/2003EP1311533A1 17-aryl-linker derivatised estrogen 3-sulphamates as inhibitors of steroid sulphatase
05/21/2003EP1311532A1 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase
05/21/2003EP1311522A1 New immunoeffector compounds
05/21/2003EP1311507A1 Fused pyrazole derivatives being protein kinase inhibitors
05/21/2003EP1311504A1 Tetrazolyl-phenyl acetamide glucokinase activators
05/21/2003EP1311503A1 Chromenone derivatives and their use for treating diseases in conjunction with 5-hta1 receptors and/or dopamine d2 receptors
05/21/2003EP1311500A2 Indole, azaindole and indazole derivatives having vegf inhibiting activity
05/21/2003EP1311489A1 Biphenyl derivatives and the use thereof as integrin inhibitors
05/21/2003EP1311478A1 Novel thiourea compounds and the pharmaceutical compositions containing the same
05/21/2003EP1311475A1 Novel aminocyclohexane derivatives
05/21/2003EP1311298A2 System for regulating in vivo the expression of a transgene by conditional inhibition
05/21/2003EP1311293A2 Combinations of ssri and estrogenic agents
05/21/2003EP1311288A1 Immunostimulatory nucleic acids for inducing a th2 immune response
05/21/2003EP1311264A1 Substituted and non-substituted benzooxathiazoles and compounds derived therefrom
05/21/2003EP1311263A2 Fused pyrrolocarbazoles against inflammation
05/21/2003EP1311258A2 Compositions containing hypotriglyceridemically active stilbenoids
05/21/2003EP1311257A2 Compositions containing hypoglycemically active stilbenoids
05/21/2003EP1311239A1 Oral delivery of peptide
05/21/2003EP1248640A4 Preparation and xenotransplantation of porcine islets
05/21/2003EP1129096B1 Crf receptor antagonists and methods relating thereto
05/21/2003EP1115701B1 Arylsulfonanilide ureas
05/21/2003EP1047668B1 Triazepinones, process for their preparation and their therapeutic application
05/21/2003EP0991616B1 METHOD FOR PRODUCING MEDICAMENTS CONTAINING HMG-CoA-REDUCTASE INHIBITORS
05/21/2003EP0866801B1 Cyclopeptolides
05/21/2003CN1419563A Peptide derivative
05/21/2003CN1419559A Tricyclic protein kinase inhibitors
05/21/2003CN1419552A 2-amino-3-(alkyl)-pyrimidone derivatives as GSKS beta. inhibitors
05/21/2003CN1419546A 4,5-dihydro-1h-pyrazole derivatives having cbi-antagonistic activity
05/21/2003CN1419539A Amidino compound and salts thereof useful as nitric oxide synahase inhibitors
05/21/2003CN1419532A Novel fatty acid analogous
05/21/2003CN1419455A Physiologically active compositions of basidiomycotina and araliaceae extracts
05/21/2003CN1419442A Method of administering a medicinal aerosol formulation
05/21/2003CN1419418A Method of producing oily suspensions of water-soluble vitamins
05/21/2003CN1419417A Carbohydrate system and a method for providing nutriton to a diabetic
05/21/2003CN1418890A Process for preparing momordic glucose-reducing polypeptide
05/21/2003CN1418889A Momordi glucose-reducing polypeptide
05/21/2003CN1418705A Mixtur eof nutrients, prepn. method and application thereof
05/21/2003CN1418700A Mayiniaotang pill for treating glucose in urine and preparation method thereof
05/21/2003CN1418692A Oral liquid for replenishing vital essence, removing dryness and reducing glucose and preparation process thereof
05/21/2003CN1418690A Erigreron Breviscapus compound preparation and medical use thereof
05/21/2003CN1418689A Medicine composition for treating diabetes, and its prepn. method
05/21/2003CN1418667A Chinese patent drug for treating diabets mellitus
05/21/2003CN1109100C Antilipemic haw vinegar and its production process
05/21/2003CN1109047C Amphiapathic moleculs as cholesterol and other lipid uptake inhibitors
05/21/2003CN1109044C Potassium glycyrrhetinic acid and productive process and use thereof
05/21/2003CN1109031C Bicycle-aromatic compound
05/21/2003CN1108812C Helath care tea and preparation method thereof
05/21/2003CN1108804C Diabetes treating medicine and its prepn. method
05/21/2003CN1108801C Phosphate-binding polymers for oral administration
05/21/2003CN1108794C Treatment medicine or precautionary medicine for hyperlipemia
05/20/2003WO2003044037A2 Process for the manufacture of human mononuclear phagocytic leukocytes
1 ... 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 ... 1298